Interactive decision aid on therapy decision making for patients with chronic kidney disease: A prospective exploratory pilot study

Abstract

Objective

Patients with advanced chronic kidney disease (CKD) face challenging decisions about kidney replacement therapy (KRT) options. This study aimed to evaluate the effectiveness of an Interactive Patient-Decision-Aid App for Kidney Replacement Therapy (iPtDA-KRT App) in improving decision self-efficacy, knowledge, and readiness while reducing decisional conflict and regret among patients with advanced CKD.

Methods

A prospective, two-arm clinical trial was conducted with 70 patients who used either the mobile app-based iPtDA-KRT or a paper-based PtDA for 4 weeks. Key measures included decision self-efficacy (DSES), decisional conflict (DCS), KRT knowledge (KRTKS), preparation for decision-making (PrepDM), and decision regret (DRS). These measures were assessed immediately post-intervention and at 4 weeks post-intervention. Additionally, outcomes such as DSES, DCS, and DRS were tracked at 8 weeks post-intervention. Data were analyzed using generalized estimating equations.

Results

The experimental group included 19 male and 16 female patients with a mean age of 66.4 ± 14.0 years, while the control group included 22 male and 13 female patients with a mean age of 59.7 ± 16.1 years. The experimental group demonstrated significantly greater and sustained improvements in self-efficacy, knowledge, and preparation for decision-making compared to the control group. Reductions in decisional conflict and regret were also maintained over time.

Conclusions

The iPtDA-KRT App demonstrated substantial and lasting benefits over paper-based PtDAs in supporting patients’ complex decision-making. These findings suggest that digital, interactive PtDAs may enhance informed decision-making, reduce long-term decisional conflict, and improve patient confidence in clinical settings.

Trial Registration

This study was registered at ClinicalTrials.gov (Identifier: NCT05666544).

Keywords

Chronic kidney disease patient decision aids kidney replacement therapy interactive simulation decisional conflict decision self-efficacy

Introduction

Chronic kidney disease (CKD) is a major global health issue, projected to be the fifth most common chronic condition by 2040.¹ Advances in medical technology have extended survival rates for CKD patients; however, most progress to kidney failure, requiring decisions about treatment options like kidney replacement therapy (KRT). Taiwan, which has the highest prevalence rate of kidney failure worldwide, has become known as a “dialysis kingdom,”² where the number of individuals undergoing dialysis continues to rise.³ Dialysis, often a lifelong treatment, not only directly affects the physical health of patients but also indirectly affects their families, employment, and the ability to participate in social activities.⁴ Therefore, patients’ preferences should be considered and patients should be involved in the decision-making process to ensure patients effectively adapt to treatments.

KRT options include hemodialysis (HD), peritoneal dialysis (PD), kidney transplantation, and conservative management. Each modality has specific pros and cons, which can be overwhelming for patients, leading to anxiety and decision-making challenges.⁵ Traditional, one-way information delivery often fails to address patients’ unique preferences and concerns. Shared decision-making (SDM), a collaborative process between healthcare providers and patients, considers patients’ perspectives crucial in forming a mutually agreed treatment plan.⁶ SDM has been shown to effectively increase medical knowledge, enhance decision-making self-efficacy, and reduce decisional conflict in patients with CKD.^7,8 In Taiwan, SDM is encouraged in CKD treatment planning. However, patients often struggle to bridge the gap between information received and real-life dialysis experiences, especially with home-based self-management requirements of PD.⁹ This discrepancy between expectation and reality can lead to confusion, regret, and feelings of powerlessness.

Patient decision aids (PtDAs) are essential components of the shared decision-making (SDM) process.¹⁰ As part of our ongoing research, we developed a web-based PtDA called the Interactive Patient-Decision-Aid App for Kidney Replacement Therapy (iPtDA-KRT App). This application integrates simulated scenarios, compares various KRT options, and translates medical evidence into patient-friendly language. Computer simulations that use sound, text, and graphics provide a practical method for presenting realistic scenarios.^11,12 Simulated scenarios engage patients in a real-life-like environment, enabling them to better integrate skills and knowledge while assisting them in overcoming the gap between expectations and reality.¹³

The Internet, as a globally accessible medium, offers significant advantages over traditional paper-based PtDAs in delivering these tools.^14–16 In recent years, information technology-based PtDAs have been widely applied in SDM across diverse healthcare fields, receiving positive evaluations for their usability and impact.^7,16,17 Historically, research on the use of web-based PDAs for KRT options has been limited. In a study conducted in the United States, Subramanian et al. (2019) provided participants with information on chronic kidney disease, peritoneal dialysis, and hemodialysis, along with a value clarification exercise, through a study website. Participants accessed this information via their personal electronic devices to support the complex decision-making process between center-based hemodialysis and peritoneal dialysis.⁷ To our knowledge, no web-based PtDA specifically designed for CKD patients choosing among KRT options has been developed in Taiwan. This could be due to the fact that traditional strategies for health education primarily involve face-to-face sessions with medical personnel. Therefore, this study aims to evaluate the impact of the developed iPtDA-KRT App on decision-making outcomes among patients with advanced CKD.

Methods

Study design

This was an exploratory pilot study using a two-arm, open-label design. The study was conducted at the nephrology outpatient clinics of two university-affiliated hospitals in central Taiwan. Both hospitals implemented a CKD care program led by the Ministry of Health and Welfare, with nephrology nurses at both sites trained in CKD care. To minimize potential institutional differences, we selected two hospitals with an established collaborative relationship, ensuring that both adhered to the same CKD care protocol and that their nephrology nurses received standardized training. One hospital was randomly assigned to the experimental group and the other to the control group through a lot-drawing method. Each group consisted of 35 participants. The experimental group used the iPtDA-KRT App, whereas the control group used the paper-based PtDA. The study was conducted from October 2022 to July 2023. Both groups completed a pretest (T0) prior to the intervention, followed by three post-tests conducted immediately after (T1), 4 weeks after the intervention (T2), and 8 weeks after the intervention ended (T3; Figure 1). Prior to data collection, researchers conducted meetings with nephrology nurses from both hospitals to ensure accuracy and procedural consistency. This study adhered to the STROBE cohort guidelines.

Figure 1.

Study flow.

The Research Ethics Committee of a medical university hospital in central Taiwan approved this study (CMUH109-REC3–085).

Decision aid development

The iPtDA-KRT App was developed in two phases, following the International Patient Decision Aid Standards.¹⁸ Phase 1 involved creating the app's prototype content through semi-structured interviews with patients and feedback from experts. A total of 15 patients, who had started dialysis within the past month and had experience with SDM and paper-based PtDAs, were recruited from a medical center. These semi-structured interviews were conducted to identify their PtDA needs. Based on these interviews, a questionnaire was developed by reviewing the literature on KRT and using an existing PtDA survey. The questionnaire included five sections covering CKD symptoms, basic information about KRT, comparisons of KRT modalities, patient preferences, and CKD/KRT information. Feedback was gathered from an expert panel using the modified Delphi method. The expert panel consisted of two nephrologists, four dialysis nurses, and a health education expert. Two rounds of the modified Delphi process were conducted to finalize the iPtDA-KRT App prototype.

The second phase focused on evaluating the iPtDA-KRT App prototype and making necessary revisions. The iPtDA-KRT App, a web-based application, was developed using JavaScript and HTML5. Testing of the prototype was carried out by the expert panel and five patients with CKD, all of whom had an educational level equivalent to junior high school. The expert panel and the patients assessed the suitability, comprehensibility, and readability of the prototype of the iPtDA-KRT App by using a structured questionnaire with items rated on a 5-point scale. The iPtDA-KRT App was refined according to the feedback from these questionnaires.

The iPtDA-KRT App (Figure 2) improves patient understanding of KRT options through three main features: (1) Interactive Guidance (Figure 2A), which provides a step-by-step walkthrough of clinical procedures; (2) Interactive Simulation (Figure 2B), which allows patients to virtually experience clinical operations via interactive videos; and (3) Interactive Decision-Making (Figure 2C), which facilitates decision-making by enabling interactive comparisons of methods, preference assessments, knowledge evaluations, and final reviews. These features empower patients to make well-informed decisions about their KRT options.

Figure 2.

The iPtDA-KRT App.

Participants

The sample size was calculated using G*Power 3.1. Based on the recommendations of the Ottawa Hospital and Health Research Institute (OHHRI), sample size estimation using the decisional conflict scale as the outcome variable should be based on an effect size of 0.3–0.4.¹⁹ The minimum required sample size was 58 participants, which was increased to 70 (approximately 35 per group) to account for potential attrition.

Participants were recruited from the outpatient clinics of two nephrologists. All potential subjects were screened to determine eligibility based on the subsequent inclusion/exclusion criteria. The inclusion criteria were as follows: (1) adults aged 20 years or older who were conscious and able to communicate in Mandarin or Taiwanese; (2) patients had an estimated glomerular filtration rate (eGFR) of less than 30 mL/min/1.73 m² (according to the recommendations of the National Kidney Foundation in the United States, education on different KRTs should begin when eGFR falls below this threshold²⁰); and (3) patients who voluntarily decided to participate in this trial and follow the trial protocol. Patients were excluded if they had absolute contraindications preventing free choice between hemodialysis and peritoneal dialysis, or if they suffered from severe illnesses or mental conditions that hindered questionnaire completion. Patients who met the inclusion criteria were referred for inclusion by nephrologists. Once patients agreed to participate, written informed consent was obtained from them prior to study initiation.

Measures

Kidney Replacement Therapy Knowledge Scale

The Kidney Replacement Therapy Knowledge Scale (KRTKS) was developed based on the Taiwan Chronic Kidney Disease Clinical Guidelines.²¹ This 10-item scale assesses knowledge of CKD and KRT, with each correct answer scoring 1 point, totaling a maximum score of 10 points. Incorrect answers receive no points.

Preparation for Decision-Making Scale

The Preparation for Decision-Making (PrepDM) Scale, developed by OHHRI, assesses patient readiness for decision-making. This 10-item scale uses a 5-point rating (1 = not at all to 5 = a great deal). Scores are calculated by subtracting the average score from 1, and then multiplying by 25, yielding a range from 0 to 100. Higher scores indicate greater readiness for decision-making.²² The scale has been confirmed to have high reliability and validity.²³

Decisional Conflict Scale

The Decisional Conflict Scale (DCS), developed by OHHRI, measures patients’ decisional conflict in medical decision-making. It consists of five subscales: informed, clarity of values, supported, uncertainty, and effective decision. Each item is rated on a 5-point scale (0 = strongly agree to 4 = strongly disagree). Scores are calculated by multiplying the average score by 25, resulting in a range from 0 to 100, with higher scores indicating more conflict.¹⁹ The DCS has demonstrated strong reliability and validity.^24–26

Decision Self-Efficacy Scale

The Decision Self-Efficacy Scale (DSES) by OHHRI measures a patient's confidence in their decision-making ability. This 11-item scale uses a 5-point rating (0 = not at all confident to 4 = very confident). The average score is multiplied by 25, yielding a score range of 0 to 100, with higher scores indicating greater decision self-efficacy.²⁷ The DSES has been validated in diverse populations.^28,29

Decision Regret Scale

The Decision Regret Scale (DRS), developed by OHHRI, evaluates the level of regret associated with health-related decisions. It includes five items rated on a 5-point scale (1 = strongly agree to 5 = strongly disagree). The second item, “I regret the choice I made,” and the fourth item, “This choice caused me a lot of harm,” are reverse-coded. Scores are converted to a 0–100 scale by subtracting 1 from each item score and multiplying by 25. Final scores are averaged, with 0 indicating no regret and 100 indicating high regret.³⁰ The DRS has been demonstrated to have high reliability and validity.^31,32

Intervention and data collection

Experimental group (iPtDA-KRT group)

Before the intervention, nephrologists and nurses at the hospital enrolling patients in the experimental group received training on the iPtDA-KRT App. At T0, demographic and disease data were collected, and participants completed the DSES, DCS, and KRTKS. The experimental group used the iPtDA-KRT App within the SDM process under the guidance of nephrology nurses, who also addressed patient questions. Participants progressed through five decision aid steps: (1) CKD symptoms and overview, (2) introduction to KRT options, (3) comparative KRT information (advantages, disadvantages, risks), with patients rating risks and benefits, (4) assessment of patient preferences and values, and (5) knowledge check on CKD and KRTs. The patient's final treatment choice was documented in the app to facilitate treatment discussions with the nephrologist.

After completing these steps, patients used the iPtDA-KRT App to discuss their choice with nephrologists and confirm their treatment plan. Following this, the first posttest (T1) was administered immediately, during which patients completed the DSES, DCS, KRTKS, and PrepDM. Patients could access the iPtDA-KRT App at home, using their accounts to review information and engage in interactive dialysis simulations for 4 weeks. Patients could determine the frequency of using the iPtDA-KRT App based on their individual preferences and needs throughout the study period. They could choose to perform any of the five decision aid steps individually or complete all steps sequentially. At the end of the 4-week period, each patient completed the second posttest (T2) at the outpatient clinics. This posttest required patients to complete the following scales: DSES, DCS, KRTKS, PrepDM, and DRS. Eight weeks after the intervention ended, all patients had a follow-up appointment, where they completed the third posttest (T3) at the outpatient clinics. This posttest required patients to complete the DSES, DCS, and DRS scales.

Control group (paper-ptDA group)

The control group received a paper-based PtDA during a face-to-face session with a nephrology nurse prior to their outpatient appointment. After this session, patients discussed their treatment options with a nephrology specialist to finalize their treatment plan. Patients were also given the paper-based PtDA to review at home. The data collection time points for the control group were identical to those of the experimental group.

Data analysis

Data were analyzed using SPSS version 24.0 (IBM, Armonk, NY, USA). Continuous variables are presented as means and standard deviations, with normality assessed using the Kolmogorov–Smirnov test, while categorical variables are shown as frequencies and percentages. Chi-square and independent t-tests were conducted to compare demographic and disease characteristics between the groups. An independent t-test analyzed pretest differences in DSES, DCS, and KRTKS scores between groups. To evaluate intervention effectiveness, paired and independent t-tests assessed changes in PrepDM and DRS scores over time within each group and between groups at each time point. A generalized estimating equation (GEE) analyzed changes in DSES, DCS, and KRTKS scores between groups post-intervention.

Results

Participant characteristics and baseline comparison

A total of 70 patients with advanced CKD were recruited, evenly divided into two groups of 35 each. No participants were lost during the study. All participants completed post-tests 4 weeks after the intervention concluded and underwent follow-up assessments at 8 weeks. The mean age of participants was 63 years (SD = 15.4), and the majority in both groups were male (58.6%), had less than a primary school education (44.3%), were married (74.2%), were unemployed (65.7%), and lived with their spouse and children (37.1%). Regarding disease status, participants had an average of 1.8 chronic conditions (SD = 1.1), a mean eGFR of 12.2 mL/min/1.73 m² (SD = 7.9), and the majority were at CKD stage 5 (67.1%). There were no significant differences in baseline demographic characteristics between groups (Table 1). At T0, no significant differences were observed between groups in DSES and DCS scores (Table 2), although the experimental group had significantly lower KRTKS scores than the control group. Further analysis of DCS subscales revealed that the experimental group scored significantly higher on the informed, values clarity, and uncertainty subscales compared to the control group.

Table 1.

Patient demographic and disease characteristics.

Variable	Total (n = 70)	iPtDA-KRT (n = 35)	Paper-PtDA (n = 35)	t/x²	P
Age (years), mean (SD)	63.0 (15.4)	66.4 (14.0)	59.7 (16.1)	1.843	.070
Gender, n (%)				0.530	.467
Male	41 (58.6)	19 (54.3)	22 (62.9)
Female	29 (41.4)	16 (45.7)	13 (37.1)
Education, n (%)				3.290	.349
Elementary school or below	31 (44.3)	14 (40.0)	17 (48.6)
Junior high school	9 (12.9)	7 (20.0)	2 (5.7)
Senior high school	18 (25.7)	8 (22.9)	10 (28.6)
University or above	12 (17.1)	6 (17.1)	6 (17.1)
Employment n (%)				2.283	.131
Unemployed	46 (65.7)	26 (74.3)	20 (57.1)
Employed	24 (34.3)	9 (25.7)	15 (42.9)
Marital, n (%)				3.197	.202
Married	52 (74.2)	28 (80.0)	24 (68.6)
Single	9 (12.9)	2 (5.7)	7 (20.0)
Divorce/Widowed	9 (12.9)	5 (14.3)	4 (11.4)
Living situation, n (%)				1.221	.748
Living alone	9 (12.9)	3 (8.6)	6 (17.1)
Live with spouse	20 (28.6)	10 (28.6)	10 (28.6)
Live with children	15 (21.4)	8 (22.9)	7 (20.0)
Live with spouse and children	26 (37.1)	14 (40.0)	12 (34.3)
eGFR, mean (SD)	12.2 (7.9)	12.9 (8.4)	11.4 (7.5)	0.796	.429
Stage, n (%)				0.583	.445
Stage 4	23 (32.9)	13 (37.1)	10 (28.6)
Stage 5	47 (67.1)	22 (62.9)	25 (71.4)
No. of chronic diseases, mean (SD)	1.8 (1.1)	1.8(1.1)	1.8 (1.1)	−0.106	.916

Abbreviations: eGFR, estimated glomerular filtration rate.

Table 2.

Baseline DSES, DCS, and KRTKS scores in each group.

	Total (n = 70)		iPtDA-KRT (n = 35)		Paper-PtDA (n = 35)
Variable	Mean	SD	Mean	SD	Mean	SD	t/x²	P
DSES	49.9	21.5	45.3	22.9	54.5	19.2	−1.824	.073
DCS	63.8	15.0	66.5	15.4	61.0	14.2	1.561	.123
Informed	59.9	19.4	65.5	19.9	54.3	17.3	2.508	.015
Values clarity	65.9	17.6	73.3	15.9	58.6	16.2	3.845	<.001
Supported	55.2	19.1	54.8	22.1	55.7	16.0	−0.207	.837
Uncertainty	71.3	17.7	76.4	16.1	66.2	17.9	2.511	.014
Effective	65.7	18.4	63.6	19.0	67.9	17.7	−0.976	.332
KRTKS	6.2	2.2	5.5	2.3	7.0	1.8	−3.132	.003

Abbreviations: DSES, Decision Self-Efficacy Scale; DCS, Decision Conflict Scale; KRTKS, Kidney Replacement Therapy Knowledge Scale.

Analysis of DSES, DCS, and KRTKS scores

Table 3 and Figure 3A show the DSES scores. In the control group, DSES increased by 20.45 points at T1 compared to T0 (P < .001) but showed no significant change at T2 (+2.66, P = .292) or T3 (−3.44, P = .176). This indicates that the initial improvement in the control group was not sustained. In contrast, the experimental group had significantly greater improvements than the control group at all post-test points: +15.71 at T1 (P < .001), +28.83 at T2 (P < .001), and +30.97 at T3 (P < .001). These results demonstrate that the iPtDA-KRT was effective at increasing DSES scores and that this effect was sustained over time.

Figure 3.

(A) DSES, (B) DCS, and (C) KRTKS score at different times.

Table 3.

Intergroup differences in intervention effectiveness of DSES, DCS, and KRTKS.

	DSES				DCS				KRTKS
Variable	B	SE	95%CI	P	B	SE	95%CI	P	B	SE	95%CI	P
Intercept	54.48	3.19	[48.2, 60.7]	<.001	60.98	2.37	[56.3, 65.6]	<.001	7.00	0.29	[6.4, 7.6]	<.001
Group
iPtDA-KRT vs. Paper	−9.22	4.98	[−18.9, 0.6]	.064	5.54	3.49	[−1.32, 12.4]	.113	−1.54	0.49	[−2.5, −0.6]	.001
Time
T1 vs. T0	20.45	3.19	[14.2, 26.7]	<.001	−15.89	1.79	[−19.4, −12.4]	<.001	1.34	0.29	[0.8, 1.9]	<.001
T2 vs. T0	2.66	2.52	[−2.3, 7.6]	.292	−2.59	1.96	[−6.4, 1.3]	.187	0.26	0.33	[−0.4, 0.9]	.441
T3 vs. T0	−3.44	2.54	[−8.4, 15.4]	.176	7.23	2.01	[3.3, 11.2]	<.001
Group x Time
iPtDA-KRT x T1 vs. Paper-PtDA x T1	15.71	4.48	[6.9, 24.5]	<.001	−27.09	3.92	[−34.8, −19.4]	<.001	2.43	0.49	[1.5, 3.4]	<.001
iPtDA-KRT x T2 vs. Paper-PtDA x T2	28.83	4.35	[20.3, 37.4]	<.001	−45.05	3.18	[−51.3, −38.8]	<.001	3.60	0.49	[2.6, 4.6]	<.001
iPtDA-KRT x T3 vs. Paper-PtDA x T3	30.97	5.12	[20.9, 41.0]	<.001	−49.78	3.97	[−57.6, −41.9]	<.001

Abbreviations: DSES, Decision Self-Efficacy Scale; DCS, Decision Conflict Scale; KRTKS, Kidney Replacement Therapy Knowledge Scale; T0, baseline; T1, first posttest (immediately after intervention); T2, second posttest (4 weeks after intervention); T3, third posttest (8 weeks after the intervention ended).

The DCS scores are presented in Table 3 and Figure 3B. In the control group, DCS decreased significantly at T1 (−15.89, P < .001) but showed no significant difference at T2 (−2.59, P = .187) and increased above T0 levels at T3 (+7.23, P < .001), indicating that the effect of the paper-based PtDA on reducing decisional conflict was not sustained. The experimental group demonstrated greater reductions in DCS than the control group at all time points: −27.09 at T1 (P < .001), −45.05 at T2 (P < .001), and −49.78 at T3 (P < .001). These results demonstrate that the iPtDA-KRT was effective in immediately reducing DCS scores and that this effect was sustained over time.

The KRTKS scores are shown in Table 3 and Figure 3C. At T0, the experimental group scored 1.54 points lower than the control group (P = .001), reflecting a lower baseline knowledge level in the experimental group. In the control group, KRTKS increased significantly at T1 (+1.34, P < .001) but showed no significant change at T2 (+0.26, P = .441), indicating that the paper-based PtDA did not have a lasting effect on knowledge improvement. The experimental group showed significantly greater increases than the control group at T1 (+2.43, P < .001) and T2 (+3.60, P < .001), demonstrating that the iPtDA-KRT effectively improved KRT knowledge, with sustained effects over time.

Analysis of prepDM scale and DRS scores

The PrepDM scale scores at T1 and T2 are presented in Table 4 and Figure 4A. Significant differences between groups were observed at both T1 and T2 (P < .001), with the experimental group demonstrating higher PrepDM scores immediately after the intervention and at 4 weeks post-intervention (T1: 73.1 [SD = 12.9] vs. 56.6 [SD = 13.8]; T2: 64.3 [SD = 13.8] vs. 43.8 [SD = 17.4]). Paired t-tests indicated that while both groups experienced a slight decrease in PrepDM scores from T1 to T2, the reduction was smaller in the experimental group compared to the control group (8.9 [SD = 20.5], P = .015 vs. 12.8 [SD = 16.8], P < .001). These findings suggest that while PrepDM scores declined in both groups at 4 weeks post-intervention, the experimental group maintained significantly higher scores, reflecting a sustained effect of the iPtDA-KRT App.

Figure 4.

(A) PrepDMS and (B) DRS score at different times.

Table 4.

Intergroup and intragroup differences in intervention effectiveness of PrepDMS and DRS.

	iPtDA-KRT (n = 35)				Paper-PtDA (n = 35)
Variable	Mean (SD)	95% CI	t	P	Mean (SD)	95% CI	t	P
PrepDMS
T1	73.1 (12.9)				56.6 (13.8)		5.196_a	<.001
T2	64.3 (13.8)				43.8 (17.4)		5.454_a	<.001
T1-T2	8.9 (20.5)	[1.8, 15.9]	2.552_b	.015	12.8 (16.8)	[7.0, 18.6]	4.505_b	<.001
DRS
T2	19.6 (9.1)				36.7 (11.7)		−6.844_a	<.001
T3	25.0 (6.5)				44.3 (12.7)		−8.005_a	<.001
T2-T3	−5.4 (12.9)	[−9.8, −1.01]	−2.498_b	.017	−7.6 (14.4)	[−12.5, −2.6]	−3.107_b	.004

Abbreviations: PrepDMS, Preparation for Decision-Making Scale; DRS, Decision Regret Scale; T1, first posttest (immediately after intervention); T2, second posttest (4 weeks after intervention); T3, third posttest (8 weeks after the intervention ended). a, Independent t test; b, Paired-t test.

The DRS scores at T2 and T3 are displayed in Table 4 and Figure 4B. Significant differences were observed between groups at both time points (P < .001), with the experimental group scoring lower in decisional regret at both 4 weeks and 8 weeks post-intervention (T2: 19.6 [SD = 9.1] vs. 36.7 [SD = 11.7]; T3: 25.0 [SD = 6.5] vs. 44.3 [SD = 12.7]). Paired t-tests revealed that while DRS scores increased slightly from T2 to T3 in both groups, the increase was smaller in the experimental group (−5.4 [SD = 12.9], P = .017) compared to the control group (−7.6 [SD = 14.4], P = .004). These results indicate that although decisional regret rose slightly over time in both groups, the experimental group's DRS scores remained significantly lower, demonstrating that the iPtDA-KRT App's effect on reducing regret was sustained.

Discussion

This study developed a digital and interactive PtDA for patients with advanced CKD to assist in deciding on KRT options. The iPtDA-KRT App was effective in enhancing patients’ decision self-efficacy and knowledge, improving readiness for decision-making, and reducing decisional conflict and regret, with these benefits sustained over time. These findings support the clinical value of digital PtDAs with simulation features to improve decision quality, achieve sustainable outcomes, and reduce decisional difficulties.

Before the intervention, the experimental group had significantly less knowledge about KRT than did the control group. Additionally, the experimental group had significantly higher baseline decisional conflict scores in the subscales of being informed, clarity of values, and uncertainty compared to the control group. This finding aligns with those of other studies indicating that patients with lower knowledge scores tend to experience greater conflict related to information and uncertainty.³³ Insufficient knowledge may prevent patients from fully understanding the benefits, risks, and side effects of treatment options, thereby increasing value conflicts as they struggle to evaluate the importance of these factors.

Our findings indicate that although the control group experienced significant short-term improvements in decision self-efficacy, knowledge, and decisional conflict immediately after the intervention, these effects diminished over time, suggesting that paper-based PtDAs do not provide lasting benefits. In contrast, the experimental group demonstrated significant and sustained improvements. Other studies have confirmed that PtDAs enhance decision self-efficacy and knowledge while reducing decisional conflict in the short term,^7,8 consistent with our findings. We demonstrated that both paper-based PtDAs and digital, interactive PtDAs elicit immediate improvements in decision-making ability. However, the immediate improvements observed in the experimental group were significantly greater than those in the control group. Although both groups experienced a decline in decision self-efficacy 4–8 weeks post-intervention, the decrease in the experimental group was significantly smaller than that in the control group. In the control group, decision self-efficacy was lower, and decisional conflict was higher at the 8 weeks after the intervention ended compared with pretest levels. Regarding knowledge, the experimental group showed a significantly greater increase in knowledge scores compared to the control group post-intervention, with these scores remaining stable over time. These findings suggest that the iPtDA-KRT App not only provides more immediate improvements in knowledge, self-efficacy, and decisional conflict compared to the paper-based PtDA but also delivers longer-lasting effects. This aligns with findings from a meta-analysis by Wu et al. (2024), which demonstrated that web-based PtDAs outperform paper-based PtDAs in reducing decisional conflict and enhancing knowledge.¹⁵ Over time, their efficacy in reducing decisional conflict remains significant. Digital tools can leverage interactive and flexible features to provide more effective support and sustain improvements in patients’ decision-making abilities.

From the perspective of long-term effects, the limitations of paper-based PtDAs are apparent. Paper-based PtDAs elicit only short-term improvements in decision self-efficacy and knowledge, likely because they lack continuous interaction and real-time feedback. Over time, patients may face recurring issues with information asymmetry and reduced self-efficacy, which can lead to increased decisional conflict. By contrast, the interactive features of the iPtDA-KRT App facilitate long-term improvements in knowledge and accuracy in risk perception. Additionally, the iPtDA-KRT App provides simulated scenarios in realistic contexts, helping patients enhance their understanding and familiarity with treatment options while reducing uncertainty about KRT choices. The convenience and flexibility of the iPtDA-KRT App enable patients to maintain higher levels of knowledge and self-efficacy even during follow-up appointments, thereby reducing decisional conflict. This highlights the dynamic adaptability of digital tools in supporting medical decision-making and addressing the personalized needs of patients more effectively.

The experimental group also demonstrated greater improvement in preparation for decision-making compared to the control group. This finding aligns with research emphasizing the benefits of interactive web-based PtDAs in improving patients’ decision readiness.^34,35 The experimental group maintained significantly higher preparation for decision-making scores up to 4 weeks post-intervention compared to pre-intervention levels, indicating that the iPtDA-KRT App effectively enhances patients’ readiness to make medical decisions. Furthermore, although preparation for decision-making began to decline 4 weeks post-intervention, the experimental group still had significantly higher scores than the control group at the 8-week follow-up. Notably, while the experimental group continued to outperform the control group in preparation for decision-making at 4 weeks, both groups exhibited a downward trend. This may reflect that patients are prone to experiencing uncertainty or emotional fluctuations during the decision-making process over time. However, the experimental group exhibited a smaller decline, indicating that the iPtDA-KRT App offers sustained decision-making support by helping patients maintain high levels of preparedness, especially in scenarios requiring long-term management or complex treatment decisions.

The experimental group demonstrated significantly greater improvement in decision regret compared to the control group. At both 4 weeks postintervention and 8 weeks after the intervention ended, the experimental group consistently had lower decision regret scores compared to the control group. Although decision regret scores in both groups increased between the 4- and 8-week follow-up visits, the experimental group maintained significantly lower scores, indicating that the iPtDA-KRT App effectively reduces patients’ negative emotions and feelings of regret, providing long-term decision support. This is particularly important because decision regret following complex and life-impacting decisions, such as those related to KRT, can have lasting effects on patients’ mental and physical well-being. Becerra et al. (2016) identified factors associated with decision regret, including higher decisional conflict, lower decision satisfaction, poorer physical health outcomes, and higher levels of anxiety.³⁶ This aligns with the present study's findings, as the experimental group demonstrated lower decisional conflict scores than the control group post-intervention, which may explain their lower decision regret scores. Thus, the continued support provided by the iPtDA-KRT App not only facilitates informed decision-making but also alleviates patients’ future psychological burdens.

Strengths and limitations

To our knowledge, this study is the first to utilize the iPtDA-KRT App to assist patients with advanced CKD in selecting a KRT modality in Taiwan, with decision quality indicators collected at multiple time points to enable a comprehensive assessment of its impact. However, several limitations should be noted. The small sample size of this pilot study may have introduced bias, and findings from two hospitals in central Taiwan may not be generalizable to other regions. Furthermore, the quasi-experimental design limited our ability to control for potential confounders, and the reliance on self-reported data may have introduced information bias. Future studies should address these limitations by increasing the sample size, expanding the geographic scope, and employing randomized controlled trials to provide more robust evidence.

Conclusions

This study highlights the benefits of digital, interactive PtDAs in enhancing patients’ self-efficacy, knowledge, and decision readiness while reducing decisional conflict and regret. The interactivity and simulated scenarios of the iPtDA-KRT App effectively support informed decision-making. As healthcare becomes increasingly digitalized, integrating PtDAs into clinical practice can enhance decision quality, reduce regret, and promote better health outcomes, highlighting their scalability and potential for widespread implementation.

Supplemental Material

sj-pdf-1-dhj-10.1177_20552076251332832 - Supplemental material for Interactive decision aid on therapy decision making for patients with chronic kidney disease: A prospective exploratory pilot study

Supplemental material, sj-pdf-1-dhj-10.1177_20552076251332832 for Interactive decision aid on therapy decision making for patients with chronic kidney disease: A prospective exploratory pilot study by Jun-Ming Su, Huey-Liang Kuo, Kai-Ling Yang, Chih-Jung Wu and Ya-Fang Ho in DIGITAL HEALTH

Supplemental Material

sj-pdf-2-dhj-10.1177_20552076251332832 - Supplemental material for Interactive decision aid on therapy decision making for patients with chronic kidney disease: A prospective exploratory pilot study

Supplemental material, sj-pdf-2-dhj-10.1177_20552076251332832 for Interactive decision aid on therapy decision making for patients with chronic kidney disease: A prospective exploratory pilot study by Jun-Ming Su, Huey-Liang Kuo, Kai-Ling Yang, Chih-Jung Wu and Ya-Fang Ho in DIGITAL HEALTH

Footnotes

ORCID iDs

Jun-Ming Su

Huey-Liang Kuo

Kai-Ling Yang

Chih-Jung Wu

Ya-Fang Ho

Acknowledgments

We highly appreciate the patients who participated in the study, which contributed greatly to this work. We also thank Cheng-Yu Hsieh for his assistance with system programming.

Ethical considerations

The Research Ethics Committee of China Medical University Hospital in Taiwan approved this study (CMUH109-REC3–085). Once patients agreed to participate, written informed consent was obtained from them prior to study initiation.

Author contributions/CRediT

YFH was responsible for this study's conceptualization, methodology, data analysis, writing, editing, and supervision. JMS was responsible for methodology, data collection and analysis, and writing. YFH and JMS drafted the manuscript. HLK and KLY were responsible for data collection and critically reviewed the manuscript. All authors have agreed on the final version.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the National Science and Technology Council, Taiwan (NSTC 112–2314-B-039-028 and NSTC 113-2410-H-024-012-MY2).

Conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Data availability

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Supplemental material

Supplemental material for this article is available online.

References

Foreman

Marquez

Dolgert

, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories. Lancet 2018; 392: 2052–2090.

United States Renal Data System . International Comparisons, https://usrds-adr.niddk.nih.gov/2023/end-stage-renal-disease/11-international-comparisons (2023, accessed 28 September 2024).

Taiwan Society of Nephrology . Incidence, https://www.tsn.org.tw/twrds.html. (2023, accessed 28 September 2024).

Chuasuwan

Pooripussarakul

Thakkinstian

, et al. Comparisons of quality of life between patients underwent peritoneal dialysis and hemodialysis: a systematic review and meta-analysis. Health Qual Life Outcomes 2020; 18: 191.

Nakayama

, et al. Shared decision-making for a dialysis modality. Kidney Int Rep 2021; 7: 15–27.

Charles

Gafni

Whelan

. Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med 1997; 44: 681–692.

Subramanian

Zhao

Zee

, et al. Use of a decision aid for patients considering peritoneal dialysis and in-center hemodialysis: a randomized controlled trial. Am J Kidney Dis 2019; 74: 351–360.

Chen

Huang

, et al. The effects of shared decision making on different renal replacement therapy decisions in patients with chronic kidney disease. J Nurs Res 2020; 28: e109.

Hsu

Yang

. Peritoneal dialysis after shared decision-making: the disparity between reality and patient expectations. BMC Nurs 2022; 21: 268.

10.

Elwyn

O'Connor

Stacey

, et al. Developing a quality criteria framework for patient decision aids: online international delphi consensus process. Br Med J 2006; 333: 417.

11.

Brown

Collins

Duguid

. Situated cognition and the culture of learning. Educational Researcher 1989; 18: 32–42.

12.

Winn

. Instructional design and situated learning: paradox or partnership. Educ Technol 1993; 33: 16–21.

13.

Bell

Maeng

Binns

. Learning in context: technology integration in a teacher preparation program informed by situated learning theory. J Res Sci Teach 2013; 50: 348–379.

14.

Baptista

Teles Sampaio

Heleno

, et al. Web-based versus usual care and other formats of decision aids to support prostate cancer screening decisions: systematic review and meta-analysis. J Med Internet Res 2018; 20: e228.

15.

Yeh

Chu

, et al. Effectiveness of computerised decision aids for patients with chronic diseases in shared decision-making: a systematic review and meta-analysis. J Clin Nurs 2024; 33: 2732–2754.

16.

Yang

, et al. Web-based decision aids to support breast cancer screening decisions: systematic review and meta-analysis. J Comp Eff Res 2020; 9: 985–1002.

17.

Tong

Geng

Wang

, et al. Web-based decision aids for cancer clinical decisions: a systematic review and meta-analysis. Support Care Cancer 2021; 29: 6929–6941.

18.

Witteman

Maki

Vaisson

, et al. Systematic development of patient decision aids: an update from the IPDAS collaboration. Med Decis Making 2021; 41: 736–754.

19.

Ottawa Hospital and Health Research Institute . Decisional Conflict Scale, https://decisionaid.ohri.ca/eval_dcs.html (2010, accessed 8 October 2022).

20.

National Kidney Foundation . K/DOQI guidelines for CKD care: chronic kidney disease: evaluation, classification, and stratification, https://www.kidney.org/guidelines-and-commentaries (2012, accessed 12 September 2022).

21.

National Health Research Institutes . Taiwan Chronic Kidney Disease Clinical Guidelines, https://www.tsn.org.tw/guide.html. (2015, accessed 2 October 2022).

22.

Ottawa Hospital and Health Research Institute . Preparation for Decision Making, https://decisionaid.ohri.ca/eval_prepdm.html (2010, accessed 8 October 2022).

23.

Bennett

Graham

Kristjansson

, et al. Validation of a preparation for decision making scale. Patient Educ Couns 2010; 78: 130–133.

24.

O'Connor

. Validation of a decisional conflict scale. Med Decis Making 1995; 15: 25–30.

25.

Guerrero-Peral

ÁL

Porta-Etessam

Rodríguez-Vico

, et al. Adaptation and validation of the spanish version of decisional conflict scale in people with migraine in Spain. Patient Prefer Adherence 2022; 16: 3291–3302.

26.

Zhai

Ning

Wang

. Psychometric evaluation of the Chinese version of decisional conflict scale in Chinese young women making HPV vaccination decisions. Patient Prefer Adherence 2022; 16: 761–769.

27.

Ottawa Hospital and Health Research Institute . Decision Self-Efficacy Scale, https://decisionaid.ohri.ca/eval_self.html (2002, accessed 8 October 2022).

28.

Bunn

O'Connor

. Validation of client decision-making instruments in the context of psychiatry. Can J Nurs Res 1996; 28: 13–27.

29.

Cranney

O'Connor

Jacobsen

, et al. Development and pilot testing of a decision aid for postmenopausal women with osteoporosis. Patient Educ Couns 2002; 47: 245–255.

30.

Ottawa Hospital and Health Research Institute . Decision Regret Scale, https://decisionaid.ohri.ca/eval_regret.html (2003, accessed 8 October 2022).

31.

Brehaut

O'Connor

Wood

, et al. Validation of a decision regret scale. Med Decis Making 2003; 23: 281–292.

32.

Calderon

Ferrando

Lorenzo-Seva

, et al. Validity and reliability of the decision regret scale in cancer patients receiving adjuvant chemotherapy. J Pain Symptom Manage 2019; 57: 828–834.

33.

Riganti

Ruiz Yanzi

Escobar Liquitay

, et al. Shared decision-making for supporting women's decisions about breast cancer screening. Cochrane Database Syst Rev 2024; 5: CD013822.

34.

Fung

Martin

Liang

, et al. Efficacy of a patient decision aid for improving person-centered decision-making by older adults with obstructive sleep apnea. J Clin Sleep Med 2021; 17: 121–128.

35.

Wang

, et al. Effects of a smartphone application named “shared decision making assistant” for informed patients with primary liver cancer in decision-making in China: a quasi-experimental study. BMC Med Inform Decis Mak 2022; 22: 145.

36.

Becerra Pérez

Menear

Brehaut

, et al. Extent and predictors of decision regret about health care decisions: a systematic review. Med Decis Making 2016; 36: 777–790.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.15 MB

0.10 MB